Sex hormone replacement therapy for individuals with Turner syndrome.
estrogen
ovarian failure
turner syndrome
Journal
American journal of medical genetics. Part C, Seminars in medical genetics
ISSN: 1552-4876
Titre abrégé: Am J Med Genet C Semin Med Genet
Pays: United States
ID NLM: 101235745
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
22
10
2018
accepted:
05
12
2018
pubmed:
28
2
2019
medline:
31
3
2020
entrez:
28
2
2019
Statut:
ppublish
Résumé
Turner syndrome is a relatively common genetic condition resulting from absence of all or part of the second sex chromosome. Individuals with Turner syndrome commonly exhibit cardiovascular, endocrine, renal, reproductive, and/or psychosocial abnormalities, among other conditions. Most girls with Turner syndrome have hypergonadotropic hypogonadism and therefore need sex steroid hormonal replacement therapy. The optimal estrogen replacement treatment regimen to induce pubertal development is still being determined. The goals of the estrogen replacement are to mimic the normal physical and social development for timing and progression of puberty. Treatment should begin at 11-12 years of age, with dose increases every 6 months over a 2-3 year period. Initiation with low doses of estrogen is crucial to preserve growth potential. On the other hand, delaying estrogen replacement may be deleterious to bone and uterine health.
Identifiants
pubmed: 30809949
doi: 10.1002/ajmg.c.31685
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-17Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR000371
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.